In a bold step toward blockchain adoption, Windtree Therapeutics, a Nasdaq-listed biotechnology firm, has announced plans to raise up to $200 million to establish a BNB crypto treasury, becoming the first public company on the Nasdaq to do so.
Windtree Signs Initial $60M Deal, Eyes $140M More
The Pennsylvania-based company confirmed that it has entered a $60 million securities purchase agreement with Build and Build Corp, a major investor in blockchain infrastructure. This deal lays the groundwork for a broader fundraising plan that could total $200 million, aimed at building a strategic reserve of BNB, the native token of the BNB Chain.
If fully executed, the move would position Windtree as a pioneer in healthcare-adjacent sectors using crypto for treasury management, joining a growing list of publicly traded firms aligning with blockchain-based assets for balance sheet diversification.
BNB: Fifth-Largest Cryptocurrency Gains Institutional Support
BNB, originally developed by Binance, has evolved into the native token of BNB Chain, a decentralized blockchain ecosystem. As of July 2025, BNB is the fifth-largest cryptocurrency by market capitalization, with increasing adoption in DeFi, gaming, and enterprise-grade applications.
Windtree’s decision to hold BNB in its corporate treasury reflects a broader shift among public companies looking to gain long-term exposure to crypto assets as inflation hedges, strategic reserves, or innovation anchors.
Why This Matters for the Crypto and Biotech Sectors
The move comes at a time when crypto treasuries are gaining credibility across industries, led by the well-publicized strategy of Michael Saylor’s firm, which now holds nearly 3% of all existing bitcoin.
Windtree’s entry into this space signals a paradigm shift in how biotech firms may finance innovation, hedge macro risk, or align with decentralized health data platforms in the future.
Conclusion
With a potential $200 million BNB treasury, Windtree Therapeutics is setting a new precedent for publicly listed firms in the life sciences sector. The deal could mark the start of broader adoption of blockchain-based treasury strategies across biotech, pharmaceuticals, and healthcare industries, as more companies seek innovative ways to future-proof their capital and operations.
Disclaimer
This content is for informational purposes only and does not constitute financial, investment, or legal advice. Cryptocurrency trading involves risk and may result in financial loss.